Gaucher Disease Treatment Market - Forecasts from 2022 to 2027
The Gaucher disease treatment market is projected to grow at a CAGR of 2.74% during the forecast period to reach US$1,223.955 million by 2027, from US$1012.952 million in 2020.
Gaucher disease is characterized by the build-up of glucocerebroside in cells and some organs, resulting in enlargement of the liver as well as the spleen. It is a genetic disease that shows symptoms such as fatigue, bruising, anemia, and a low blood platelet count and is caused by a hereditary deficit of the enzyme glucocerebrosidase. Despite being the most common lysosomal storage disorder, Gaucher disease is a rare ailment with an incidence of 1 in 100,000 people.
One of the key reasons driving the Gaucher disease treatment market during the forecast period is the rising prevalence of Gaucher worldwide. Factors such as increasing Gaucher disease incidences and pharmaceutical companies' increased focus on developing innovative pharmaceuticals for treating Gaucher disease are likely to contribute to the market's growth significantly. Furthermore, rising concern for the growing incidences of Gaucher disease amongst people worldwide, combined with increasing government support and funding and rising per capita healthcare expenditure by several nations worldwide, are some of the factors expected to drive the growth of the global Gaucher disease market. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6 percent in 2019 to US$ 3.8 trillion, or US$ 11,582 per person, accounting for 17.7 percent of GDP. Furthermore, the federal government accounted for 29.0 percent of total health expenditures, with families coming in second (28.4 percent). State and municipal governments accounted for 16.1 percent of overall healthcare expenditures, with other private sources accounting for the remaining 7.5 percent.
The market for Gaucher treatment may be limited by the high cost of treatment for the condition. Stringent government regulations governing the use of medications and therapies for the condition, as well as the high cost of enzyme replacement therapy and a lack of therapeutic options in poorer nations, may have an impact on market growth.
In 2021, the National Gaucher Foundation (NGF) started the Stepping Stones sustainer donating program. The long-term goal of this strategy is to provide a consistent source of funding for patient advocacy programs and provide financial assistance to the 6,000 persons in the United States who have Gaucher disease. Lysogene announced a research partnership with the Weizmann Institute of Science in July 2020 to produce a unique AAV gene therapy strategy for neuronopathic Gaucher's disease, Parkinson's disease, and other disorders caused by the GBA1 gene abnormalities. In 2020, Centogene and Evotec expanded their drug discovery collaboration focused on the protein target glucocerebrosidase, focusing on Gaucher's Disease. Gain Therapeutics, Inc. made a significant breakthrough in November 2021 in the potential to treat neurodegenerative disorders characterized by misfolded proteins, such as Alzheimer's Disease, Gaucher's Disease, and Parkinson's Disease.
By treatment type, the Gaucher disease treatment market is segmented into Enzyme Replacement Treatment type (ERT), Substrate Reduction Treatment (SRT), and surgical procedures. The ERT segment is expected to have a dominant market position owing to the rising global use of treating Gaucher disease and improved knowledge of the use of Enzyme Replacement Treatment.
By disease type, the Gaucher disease treatment market is segmented into Type I, Type II, and Type III. Due to the increasing number of patients suffering from type I Gaucher disease worldwide, type I Gaucher disease is seen to be the market's dominant category. Type I Gaucher affects around 95 percent of the population, making it the most common type of disease, according to the National Gaucher Foundation.
By end-users, the Gaucher disease treatment market is segmented into hospitals, ambulatory surgical centers, and clinical research institutes. Preference for hospitals is expected to fuel the segment's growth due to the availability of innovative technology and many facilities available on a single site.
By geography, the Gaucher disease treatment market is segmented into five regions - North America, Europe, South America, the Middle East and Africa, and Asia Pacific regions. North America is expected to have the most significant market share in the Gaucher disease treatment market due to the increasing number of people suffering from the condition and expanding awareness of the utilization of effective treatment alternatives. The presence of prominent market players in the region, as well as their revenue-generating tactics, is also propelling the regional market forward. Because of increased awareness initiatives about Gaucher disease treatment, the European Gaucher disease treatment market is likely to remain the second-largest market.
The COVID-19 epidemic has resulted in various hurdles to medical care delivery, which vary based on a patient's underlying illness. Because of the pandemic, lockdown measures were implemented, prohibiting patient movement and identification, as well as severely overburdening healthcare institutions while raising concerns among patients. It will have a significant impact on the Gaucher disease treatment market. The COVID 19 outbreak would result in excessively long wait times for patients needing certain treatments.
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Ambulatory Specialty Clinics
Clinical Research Institutes
Middle East and Africa